Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis

New non-steroidal anti-inflammatory drugs: Selective inhibitors of the inducible cyclooxygenase

“…Insgesamt ergibt sich s252 Nabumeton eine geringe Bevorzugung f'ª die COX-2; eine der Salicyls~ure vergleichbare COX-2-Selektivit~it bestehtjedoch nicht. Entsprechend dieses relativ gª Wirkprofils belegen klinische Studien, dal3 Nabumeton bei guter antiphlogistischer Wirksamkeit seltener zu gastrointestinalen Nebenwirkungen s als Naproxen, Indometacin, Piroxicam, Ibuprofen oder Diclofenac [9,63,64]. Renale Nebenwirkungen sind unter Nabumeton selten -unabh~ingig vom Lebensalter [4].…”

Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance

“…Both have shown anti-inflammatory efficacy similar to other NSAIDs, as well as a low incidence of gastroerosive side effects. [13][14][15][16][17][18] Nabumetone is a prodrug of the 2,6-disubstituted naphthyl alkanone class. It is metabolized in the liver to its active metabolite, 6-methoxy-2-naphthylacetic acid.…”

Second-line drug therapy for osteoarthritis

“…Additionally, the magnitude of improvement in joint pain achieved today with first-line agents is only modest. Based on measurements on visual analogue scales, improvement in joint pain with the currently available agents is only 20-25%, while that with placebo may be 15% [24][25][26][27] . This may account for the observation that only about 15% of patients with OA who were started on an NSAID were still taking the same NSAID 12 months later 28 .…”